[{"indications": "Indications\u00a0\n(From Retigabine: British National Formulary)\nRetigabine", "name": "RETIGABINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.8 Antiepileptic drugs", "4.8.1 Control of the epilepsies", "Retigabine"], "cautions": "Cautions\u00a0avoid abrupt withdrawal; risk of urinary retention; known QT-interval prolongation (see below); interactions: see Interactions in section\r\n4.8.1 and Appendix 1 (retigabine)QT-interval prolongation\u00a0Patients with known QT-interval\r\nprolongation, or with the following risk factors for QT-interval prolongation,\r\nshould be carefully monitored while taking retigabine: cardiac failure, ventricular hypertrophy, electrolyte abnormalities, or concomitant treatment with drugs that can prolong QT interval", "side-effects": "Side-effects\u00a0increased appetite, weight gain, nausea, constipation,\r\ndyspepsia, dry mouth, peripheral oedema, malaise, drowsiness, dizziness,\r\nvertigo, amnesia, paraesthesia, tremor, impaired coordination, impaired\r\nspeech and attention, myoclonus, confusion, psychosis, anxiety, dysuria,\r\nhaematuria, diplopia, blurred vision; less commonly dysphagia, hypokinesia, urinary retention, nephrolithiasis, rash,\r\nsweating; suicidal ideation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/214617.htm", "doses": ["adult over 18 years, initially\r\nup to 300\u00a0mg daily in 3 divided doses, increased according to response\r\nby up to 150\u00a0mg every week up to maintenance dose of 0.6\u20131.2\u00a0g daily; elderly over 65 years, initially 150\u00a0mg daily in\r\n3 divided doses, increased according to response by up to 150\u00a0mg every\r\nweek; max. 900\u00a0mg daily"], "pregnancy": "Pregnancy\u00a0see Pregnancy"}]